Xenon Pharmaceuticals Inc.

XENE - CIK 0001582313

Market cap$4.96 B

Rank#1390

SEC filings763

Xenon Pharmaceuticals Inc. trades as XENE and has a market capitalization of $4.96 B, making it the #1390 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $7.50M and net income of -$345.91M. This page tracks Xenon Pharmaceuticals Inc. through 763 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$7.50MFY 2025

Net income (latest FY)-$345.91MFY 2025

Operating cash flow (latest FY)-$279.12MFY 2025

Total assets (latest FY)$633.16MFY 2025

Net margin-4612.1%latest FY

Financial performance

Over the last 10 fiscal years Xenon Pharmaceuticals Inc.'s revenue declined from $15.58M to $7.50M, a compound annual decline rate of 7.0%. Net profit margin compressed from -1275.5% to -4612.1% over the same period - every figure below comes from the company's audited annual filings.

XENE annual revenueView details

Key statistics

Market cap: $4.96 B
Share price (derived)market cap / shares outstanding: $51.34
EPS (diluted)FY 2025: $-4.36
Shares outstandingas of 2026-05-04: 0.10B
Total equityas of 2026-03-31: $1.34B
Return on equity: -25.9%
Cash & equivalentsas of 2026-03-31: $545.87M
Current ratioas of 2026-03-31: 27.79

Latest filings

Filing	Type	Filed
SCHEDULE 13G/A	-	2026-05-15
SCHEDULE 13G/A	-	2026-05-15
SCHEDULE 13G/A	-	2026-05-15
Insider trade	4	2026-05-13
Quarterly report	10-Q	2026-05-07
Major company event	8-K	2026-05-07
Annual report to shareholders	ARS	2026-04-22
Proxy materials	DEFA14A	2026-04-22

Browse the full filing history (763 filings)

Recent press releases

Xenon Reports Q1 2026 Financial Results and Provides Business Update2026-05-07
Xenon Reports Q1 2026 Financial Results and Provides Business Update | Xenon Pharmaceuticals Inc.
Xenon to Report Q1 2026 Financial Results on May 7, 20262026-05-07
(800) 715-9871 toll-free or (646) 307-1963 for international callers
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2026-05-01
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Xenon Pharmaceuticals Inc.
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting2026-04-19
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting | Xenon Pharmaceuticals Inc.
Xenon to Present at Upcoming Investor Conferences2026-04-15
Xenon to Present at Upcoming Investor Conferences | Xenon Pharmaceuticals Inc.

Similar companies

The largest companies sharing Xenon Pharmaceuticals Inc.'s SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.070 T XENE vs LLY

JNJJohnson & Johnson$574.10 B XENE vs JNJ

ABBVAbbVie Inc.$397.44 B XENE vs ABBV

MRKMerck & Co., Inc.$294.13 B XENE vs MRK

AZNAstraZeneca PLC$286.27 B XENE vs AZN

Frequently asked questions

What is Xenon Pharmaceuticals Inc.'s market cap?

Xenon Pharmaceuticals Inc. (XENE) has a market capitalization of $4.96 B as of 2026-06-11, ranking #1390 among US-listed companies.

How much revenue does Xenon Pharmaceuticals Inc. make?

Xenon Pharmaceuticals Inc. reported revenue of $7.50M for fiscal year 2025.

Is Xenon Pharmaceuticals Inc. profitable?

In its latest fiscal year Xenon Pharmaceuticals Inc. reported a net loss of $345.91M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.